2024 was a mixed year for biopharma stocks, with the iShares Biotechnology ETF and SPDR S&P Biotech ETF experiencing small decreases. Federal Reserve decisions caused a 10-day decline in biotech ETFs. StockWatch’s top five performing biotech stocks include Bright Minds Biosciences and Monopar Therapeutics while the biggest laggards were Aditxt and CNS Pharmaceuticals. Mesoblast’s American Depositary Receipts rose significantly due to FDA approval of its Ryoncil treatment.
BadBox rapidly grows, 190,000 Android devices infected
A botnet known as BadBox has infected 190,000 Android devices, surveillance data from Bitsight has revealed. The botnet primarily targets Yandex smart TVs and Hisense
